0000899243-23-015632.txt : 20230615 0000899243-23-015632.hdr.sgml : 20230615 20230615180148 ACCESSION NUMBER: 0000899243-23-015632 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230613 FILED AS OF DATE: 20230615 DATE AS OF CHANGE: 20230615 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZDRAVESKI ZORAN CENTRAL INDEX KEY: 0001741285 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 231018772 MAIL ADDRESS: STREET 1: C/O MAGENTA THERAPEUTICS STREET 2: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-13 0 0001783328 TScan Therapeutics, Inc. TCRX 0001741285 ZDRAVESKI ZORAN C/O TSCAN THERAPEUTICS, INC. 830 WINTER STREET WALTHAM MA 02451 0 1 0 0 Chief Legal Officer 0 Stock Option (Right to Buy) 2.49 2023-06-13 4 A 0 430000 0.00 A 2033-06-12 Voting Common Stock 430000 430000 D 220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023. /s/ Zoran Zdraveski 2023-06-15